Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lunbiao Cui

Showing results (91-100 of 101) with videos related to

Pageof 11
Sort By:
Journal of Clinical Microbiology|September 21, 2012
Detection of severe fever with thrombocytopenia syndrome virus by reverse transcription-cross-priming amplification coupled with vertical flow visualizationLunbiao Cui, Yiyue Ge, Xian Qi, et al.
Scientific Reports|July 28, 2017
Increased Prevalence of Severe Fever with Thrombocytopenia Syndrome in Eastern China Clustered with Multiple Genotypes and Reasserted Virus during 2010-2015Zhifeng Li, Jianli Hu, Lunbiao Cui, et al.
Frontiers in Public Health|August 20, 2025
Respiratory pathogens in infants and young children with acute respiratory illness: a prospective cohort study, China, 2023-2024Yuqing Li, Mingwei Wei, Lunbiao Cui, et al.
Journal of Virology|November 21, 2020
HTCC as a Polymeric Inhibitor of SARS-CoV-2 and MERS-CoVAleksandra Milewska, Ying Chi, Artur Szczepanski, et al.
Nature Medicine|January 28, 2022
Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trialJingxin Li, Lihua Hou, Xiling Guo, et al.
Emerging Microbes & Infections|December 12, 2022
Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trialLairun Jin, Rong Tang, Shipo Wu, et al.
Expert Review of Vaccines|November 11, 2024
Immunogenicity and safety of two-dose or three-dose regimens of inactivated COVID-19 vaccines in patients with pulmonary tuberculosis: a randomised clinical trialPengfei Jin, Qiao Liu, Wenli Chen, et al.
Signal Transduction and Targeted Therapy|April 25, 2021
An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19Yiyue Ge, Tingzhong Tian, Suling Huang, et al.
The Lancet. Respiratory Medicine|June 1, 2022
Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trialsFengcai Zhu, Chunlan Zhuang, Kai Chu, et al.
Nature Communications|January 25, 2014
Dynamic reassortments and genetic heterogeneity of the human-infecting influenza A (H7N9) virusLunbiao Cui, Di Liu, Weifeng Shi, et al.
Pageof 11

Showing results (91-100 of 101) with videos related to

Sort By:
Pageof 11
Journal of Clinical Microbiology|September 21, 2012
Detection of severe fever with thrombocytopenia syndrome virus by reverse transcription-cross-priming amplification coupled with vertical flow visualizationLunbiao Cui, Yiyue Ge, Xian Qi, et al.
Scientific Reports|July 28, 2017
Increased Prevalence of Severe Fever with Thrombocytopenia Syndrome in Eastern China Clustered with Multiple Genotypes and Reasserted Virus during 2010-2015Zhifeng Li, Jianli Hu, Lunbiao Cui, et al.
Frontiers in Public Health|August 20, 2025
Respiratory pathogens in infants and young children with acute respiratory illness: a prospective cohort study, China, 2023-2024Yuqing Li, Mingwei Wei, Lunbiao Cui, et al.
Journal of Virology|November 21, 2020
HTCC as a Polymeric Inhibitor of SARS-CoV-2 and MERS-CoVAleksandra Milewska, Ying Chi, Artur Szczepanski, et al.
Nature Medicine|January 28, 2022
Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trialJingxin Li, Lihua Hou, Xiling Guo, et al.
Emerging Microbes & Infections|December 12, 2022
Antibody persistence and safety after heterologous boosting with orally aerosolised Ad5-nCoV in individuals primed with two-dose CoronaVac previously: 12-month analyses of a randomized controlled trialLairun Jin, Rong Tang, Shipo Wu, et al.
Expert Review of Vaccines|November 11, 2024
Immunogenicity and safety of two-dose or three-dose regimens of inactivated COVID-19 vaccines in patients with pulmonary tuberculosis: a randomised clinical trialPengfei Jin, Qiao Liu, Wenli Chen, et al.
Signal Transduction and Targeted Therapy|April 25, 2021
An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19Yiyue Ge, Tingzhong Tian, Suling Huang, et al.
The Lancet. Respiratory Medicine|June 1, 2022
Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trialsFengcai Zhu, Chunlan Zhuang, Kai Chu, et al.
Nature Communications|January 25, 2014
Dynamic reassortments and genetic heterogeneity of the human-infecting influenza A (H7N9) virusLunbiao Cui, Di Liu, Weifeng Shi, et al.
Pageof 11